

**Dr. Martens plc**

**Director/PDMR Shareholding**

**Notification of Transactions by Director/Person Discharging Managerial Responsibility**

Dr. Martens plc (the 'Company') announces that it has been notified of the following transaction(s) in the Company's Ordinary Ip shares undertaken on behalf of a director and person discharging managerial responsibility ('PDMR').

On 15 April 2025, a tranche of restricted stock units ('RSUs') granted to Ije Nworie under the Company's Long Term Incentive Plan ('LTIP') prior to his appointment as Chief Executive Officer vested and sufficient shares were subsequently sold on his behalf to cover his consequent tax and national insurance liabilities.

This tranche constitutes a portion of the RSU award which was granted to Ije on 14 June 2024 in lieu of outstanding incentive awards he forfeited on leaving his previous employer (the 'Award'). The Award was made pursuant to the buyout arrangements agreed to secure Ije's recruitment to his previous role as Chief Brand Officer, which he held from February 2024 until rejoining the Board as Chief Executive Officer in January 2025, and in line with the stipulations of the Company's Remuneration Policy that 'buyout awards' be granted on a like-for-like basis to the extent possible. Full details of awards made to Ije under the LTIP will be disclosed in the Directors' Remuneration Report within the FY25 Annual Report, scheduled to be released in June 2025.

The relevant notifications, set out below, are provided in accordance with the requirements of Article 19 of the Market Abuse Regulation.

1	Details of the person discharging managerial responsibilities/person closely associated		
a)	Name	Ije Nworie	
2	Reason for the notification		
a)	Position/status	PDMR (Chief Executive Officer)	
b)	Initial notification/Amendment	Initial notification	
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	Dr. Martens plc	
b)	LEI	213800QPT8YM6NQZPH28	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument  Identification code	Ordinary shares of GBP 0.01  ISIN: GB00BL6NGV24	
b)	Nature of the transaction	Acquisition of shares following vesting of restricted stock units	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		Nil	621,911
d)	Aggregated information  - Aggregated volume  - Price	N/A - single transaction	
e)	Date of the transaction	15 April 2025	
f)	Place of the transaction	Outside a trading venue	

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name	Ije Nworie
2	Reason for the notification	
a)	Position/status	PDMR (Chief Executive Officer)
b)	Initial notification/Amendment	Initial notification

3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	Dr. Martens plc	
b)	LEI	213800QPT8YM6NQZPH28	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of GBP 0.01  ISIN: GB00BL6NGV24	
b)	Nature of the transaction	Sale of sufficient shares acquired from vesting of restricted stock units to cover tax and national insurance liabilities.	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		0.509239	293,328
d)	Aggregated information - Aggregated volume  - Price	N/A - single transaction	
e)	Date of the transaction	15 April 2025	
f)	Place of the transaction	XLON	

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHUNSORVOUSAAR